iatroX logo
brainstormaskiatroX
knowledge centreblog
Knowledge Centre / Adult-Onset Still's Disease (AOSD)

Adult-Onset Still's Disease (AOSD)

Overview and management.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
Rheumatology

Clinical Guidelines

NHS England Clinical Commissioning Policy: Tocilizumab for the treatment of adult onset Still’s disease (AOSD)
National
NICE technology appraisal guidance [TA685]: Anakinra for treating Still's disease
National
EULAR/PReS recommendations for the diagnosis and management of systemic juvenile idiopathic arthritis and adult-onset Still's disease
Local
EULAR/PReS recommendations for the diagnosis and management of systemic juvenile idiopathic arthritis and adult-onset Still's disease
Local
EULAR/PReS recommendations for the diagnosis and management of systemic juvenile idiopathic arthritis and adult-onset Still's disease
Local

Recent iatroX Q&As

  • Which laboratory tests are most useful in confirming a diagnosis of Adult-Onset Still's Disease?Updated: 8/17/2025
  • What are the recommended first-line treatment options for managing Adult-Onset Still's Disease in adults?Updated: 8/17/2025
  • When should I consider referring a patient with suspected Adult-Onset Still's Disease to a rheumatologist?Updated: 8/17/2025
askiatroX
privacytermshow it workscpdinsights
Download on the App StoreGet it on Google Play